Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Deborah J. Heath"'
Autor:
Clive Buckle, Holly Evans, Deborah J. Heath, John D. Shaughnessy, David R. Stover, Les Coulton, Peter I. Croucher, Karin Vanderkerken, John A. Snowden, Andrew D Chantry
Publikováno v:
Vrije Universiteit Brussel
Multiple myeloma (MM) is associated with the development of osteolytic bone disease, mediated by increased osteoclastic bone resorption and impaired osteoblastic bone formation. Dickkopf-1 (Dkk1), a soluble inhibitor of wingless/int (Wnt) signaling a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84d292594c640855652ed9a0110aa9ba
https://hdl.handle.net/20.500.14017/f0bfb978-dc99-49e9-89cf-3e54cb362b27
https://hdl.handle.net/20.500.14017/f0bfb978-dc99-49e9-89cf-3e54cb362b27
Autor:
E. Terpos, Dimitrios Christoulas, Evangelos Eleftherakis-Papaiakovou, Efstathios Kastritis, Deborah J. Heath, Peter I. Croucher, Konstantinos Tsionos, Meletios A. Dimopoulos, Maria Roussou, N. Anagnostopoulos
Publikováno v:
Leukemia. 22(12)
This phase 2 study aimed to determine the efficacy and safety of the combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide (VMDT) and its effect on bone remodeling and angiogenesis in relapsed/refractory myeloma. Bortezomib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::774a108912165fe9aaac046a137f2364
https://pubmed.ncbi.nlm.nih.gov/18769451
https://pubmed.ncbi.nlm.nih.gov/18769451
Autor:
Deborah J. Heath, Matthew Prideaux, Xin Cheng, Karin Vanderkerken, Peter I. Croucher, Ramachandran Murali, Orla Gallagher
Publikováno v:
Cancer research. 67(1)
Multiple myeloma is a B-cell malignancy characterized by the uncontrolled growth of plasma cells in the bone marrow and the development of osteolytic bone disease. Myeloma cells express the receptor activator of nuclear factor κB ligand (RANKL), ind
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6d5627a1855c3ecb19438bf21b4efe4
https://pubmed.ncbi.nlm.nih.gov/17210700
https://pubmed.ncbi.nlm.nih.gov/17210700
Autor:
Peter I. Croucher, Andrew D Chantry, Deborah J. Heath, Evgenia Verrou, Evangelos Terpos, Athanasios Anagnostopoulos, Meletios-Athanassios Dimopoulos, Kostas Zervas, Eirini Katodritou, Amin Rahemtulla, Anastasia Pouli, Elisavet-Christine Vervessou
Publikováno v:
British journal of haematology. 135(5)
Summary The effect of bortezomib on bone remodelling was evaluated in 34 relapsed myeloma patients. At baseline, patients had increased serum concentrations of dickkopf-1 (DKK-1), soluble receptor activator of nuclear factor-jB ligand (sRANKL), sRANK
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99af93a5eb7cf4d6dda98c2956bd3245
https://pubmed.ncbi.nlm.nih.gov/17107351
https://pubmed.ncbi.nlm.nih.gov/17107351
Autor:
Richard Szydlo, Meletios A. Dimopoulos, Deborah J. Heath, Athanasios Anagnostopoulos, Peter I. Croucher, Evangelos Terpos, Amin Rahemtulla, Marianna Politou
Publikováno v:
International journal of cancer. 119(7)
Dickkopf-1 (DKK-1) protein, a soluble inhibitor of Wnt signalling, has been implicated in the pathogenesis of myeloma bone disease through the suppression of osteoblast differentiation. In this study, serum concentrations of DKK-1 were measured in 50
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3d876f59843ec2499271482db2da948
https://pubmed.ncbi.nlm.nih.gov/16646053
https://pubmed.ncbi.nlm.nih.gov/16646053
Publikováno v:
Stem cells (Dayton, Ohio). 22(5)
Through their broad differentiation potential, mesenchymal stem cells (MSCs) are candidates for a range of therapeutic applications, but the precise signaling pathways that determine their differentiated fate are not fully understood. Evidence is eme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::760ad1f69b66303ba439940140e2e474
https://pubmed.ncbi.nlm.nih.gov/15342948
https://pubmed.ncbi.nlm.nih.gov/15342948
Autor:
Jas Seehra, Les Coulton, Karin Vanderkerken, Deborah J. Heath, Holly Evans, Nicole Abdul, Peter I. Croucher, Andrew D Chantry
Publikováno v:
Cancer Treatment Reviews. 34:13-14
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1cacbbaa77ba79653af4081bfaf9cd1b
https://doi.org/10.1016/j.ctrv.2008.03.044
https://doi.org/10.1016/j.ctrv.2008.03.044
Autor:
Konstantinos Tsionos, Efstathios Kastritis, Nikolaos Anagnostopoulos, Peter I. Croucher, Dimitrios Christoulas, Maria Roussou, Meletios A. Dimopoulos, Deborah J. Heath, Evangelos Terpos, Athanasios Anagnostopoulos
Publikováno v:
Blood. 108:3541-3541
Bortezomib (V) and thalidomide (T) exert their anti-myeloma (MM) action partly through perturbation of the MM microenvironment. The aim of this phase II study was to determine the efficacy and safety of the combination of VT with melphalan (M) and de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::715a3659b8ce1bb34e3c3b5cbe26b29f
https://doi.org/10.1182/blood.v108.11.3541.3541
https://doi.org/10.1182/blood.v108.11.3541.3541
Autor:
Elisavet C. Vervessou, Deborah J. Heath, Evgenia Verrou, Kostas Zervas, Evangelos Terpos, Andrew D Chantry, Athanasios Anagnostopoulos, Meletios A. Dimopoulos, Amin Rahemtulla, Peter I. Croucher, Anastasia Pouli, Eirini Katodritou
Publikováno v:
Blood. 108:506-506
Bortezomib is a proteasome inhibitor, which is currently indicated for the treatment of relapsed/refractory myeloma (MM). Although the anti-myeloma effect of bortezomib has been clearly demonstrated, its effect on bone metabolism is still unclear. Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4218ffa83648f166065a627d8ff1d3fa
https://doi.org/10.1182/blood.v108.11.506.506
https://doi.org/10.1182/blood.v108.11.506.506